📗 Cite This Artifact
Lithium for PSP/CBS — Phase 2 Trial
Path: /clinical-trials/lithium-psp-phase-2-nct05297202 NCT ID: NCT05297202 Phase: Phase 2 Status: Recruiting Sponsor: Academic/NIH-funded Study Start: 2022
Trial Overview
This Phase 2 clinical trial evaluates low-dose lithium as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Both are 4R-tauopathies characterized by tau pathology, and lithium's GSK-3beta inhibition targets the shared tau hyperphosphorylation mechanism underlying neurodegeneration in these conditions.
Path: /clinical-trials/lithium-psp-phase-2-nct05297202 NCT ID: NCT05297202 Phase: Phase 2 Status: Recruiting Sponsor: Academic/NIH-funded Study Start: 2022
Trial Overview
This Phase 2 clinical trial evaluates low-dose lithium as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Both are 4R-tauopathies characterized by tau pathology, and lithium's GSK-3beta inhibition targets the shared tau hyperphosphorylation mechanism underlying neurodegeneration in these conditions.
The trial represents a critical test of the hypothesis that GSK-3beta inhibition can slow disease progression in pure tauopathies, building on previous mixed results from lithium trials in Alzheimer's disease. By targeting patients earlier in disease progression and focusing on PSP/CBS as "pure" tauopathies without significant amyloid co-pathology, this trial addresses key limitations of prior studies.
This Phase 2 clinical trial evaluates low-dose lithium as a potential disease-modifying treatment for progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), both representing devastating 4R-tauopathies characterized by progressive tau pathology, neuronal loss, and relentless clinical decline. The trial leverages lithium's well-established activity as a glycogen synthase kinase-3 beta (GSK-3beta) inhibitor to target the fundamental tau hyperphosphorylation mechanism that drives neurofibrillary tangle formation in both conditions.
The rationale for this trial stems from decades of research establishing GSK-3beta as a central kinase responsible for pathological tau phosphorylation. By inhibiting GSK-3beta activity, lithium may reduce tau phosphorylation at multiple canonical sites, decrease tau aggregation propensity, and potentially slow the progression of tau-mediated neurodegeneration. Importantly, this approach targets a shared mechanism across PSP and CBS, offering the potential for a therapy that addresses the underlying pathophysiology common to both disorders.
Background: 4R-Tauopathies
PSP (Progressive Supranuclear Palsy)
PSP is a distinct clinical syndrome classified as a 4R-tauopathy due to the predominant accumulation of 4-repeat tau isoforms in neurofibrillary tangles. The disease was first described by John Steele, Jerzy Olszewski, and John Richardson in 1963, hence the alternative name Steele-Richardson-Olszewski syndrome.
Core Clinical Features:
- Vertical supranuclear gaze palsy (especially downward)
- Postural instability with frequent falls (within first year)
- Akinesia and rigidity (axial > appendicular)
- Cognitive decline (dysexecutive pattern)
Variants:
- PSP-parkinsonism (PSP-P): Features asymmetric tremor, initial levodopa responsiveness
- PSP-cortical basal syndrome (PSP-CBS): Overlaps with corticobasal degeneration pathology
- PSP-pure akinesia with gait freezing: Predominant gait and freezing without other features
The Richardson's Syndrome-Parkinsonism (PSP-RS/P) classification reflects clinical heterogeneity within the PSP spectrum.
CBS (Corticobasal Syndrome)
CBS represents the clinical manifestation of corticobasal degeneration (CBD), another 4R-tauopathy. The syndrome features:
- Asymmetric rigidity (more pronounced on one side)
- Apraxia (ideomotor, limb)
- Cortical sensory loss (two-point discrimination, stereognosis)
- Alien limb phenomenon (involuntary limb movements)
- Myoclonus (often action-induced)
- Dysarthria (spastic/ataxic)
PSP and CBS Share Critical Pathological Features
Shared 4R-Tauopathy: Both conditions are classified as 4R-tauopathies, characterized by elevated inclusion of the four-repeat tau isoform in neurofibrillary tangles. This is distinct from Alzheimer's disease, which involves both 3R and 4R tau isoforms.
Common Tau Pathology Mechanism: In both PSP and CBS, the tau protein undergoes hyperphosphorylation at multiple serine and threonine residues, mediated in large part by GSK-3β. This hyperphosphorylation reduces tau's ability to bind microtubules, promotes tau misfolding, and drives the formation of toxic oligomers and filaments.
GSK-3β Overactivity: Multiple lines of evidence suggest that GSK-3β activity is increased in the brains of patients with PSP and CBS, contributing to the observed tau pathology. This provides a mechanistic rationale for therapeutic intervention.
Unmet Medical Need: Both PSP and CBS lack disease-modifying therapies. Current treatments address only symptoms and do not slow disease progression. The development of a tau-directed therapy represents a critical unmet need.
GSK-3β Biology in Tauopathies
The Role of GSK-3β in Normal Neuronal Function
Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase with diverse physiological functions in the central nervous system:
This Phase 2 clinical trial evaluates low-dose lithium as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Both are 4R-tauopathies characterized by tau pathology, and lithium's GSK-3β inhibition targets the shared tau hyperphosphorylation mechanism underlying neurodegeneration in these conditions[@forlenza2023].
The trial represents a critical test of the hypothesis that GSK-3β inhibition can slow disease progression in pure tauopathies, building on previous mixed results from lithium trials in Alzheimer's disease. By targeting patients earlier in disease progression and focusing on PSP/CBS as "pure" tauopathies without significant amyloid co-pathology, this trial addresses key limitations of prior studies.
Background: 4R-Tauopathies
PSP (Progressive Supranuclear Palsy)
PSP is a distinct clinical syndrome classified as a 4R-tauopathy due to the predominant accumulation of 4-repeat tau isoforms in neurofibrillary tangles. The disease was first described by John Steele, Jerzy Olszewski, and John Richardson in 1963, hence the alternative name Steele-Richardson-Olszewski syndrome.
Core Clinical Features:
- Vertical supranuclear gaze palsy (especially downward)
- Postural instability with frequent falls (within first year)
- Akinesia and rigidity (axial > appendicular)
- Cognitive decline (dysexecutive pattern)
Variants:
- PSP-parkinsonism (PSP-P): Features asymmetric tremor, initial levodopa responsiveness
- PSP-cortical basal syndrome (PSP-CBS): Overlaps with corticobasal degeneration pathology
- PSP-pure akinesia with gait freezing: Predominant gait and freezing without other features
The Richardson's Syndrome-Parkinsonism (PSP-RS/P) classification reflects clinical heterogeneity within the PSP spectrum.
CBS (Corticobasal Syndrome)
CBS represents the clinical manifestation of corticobasal degeneration (CBD), another 4R-tauopathy. The syndrome features:
- Asymmetric rigidity (more pronounced on one side)
- Apraxia (ideomotor, limb)
- Cortical sensory loss (two-point discrimination, stereognosis)
- Alien limb phenomenon (involuntary limb movements)
- Myoclonus (often action-induced)
- Dysarthria (spastic/ataxic)
Importantly, approximately 40% of CBS cases at autopsy show PSP pathology, highlighting the pathological overlap between these conditions. This trial includes both conditions because they share the target (4R-tau) and the mechanism (GSK-3β-mediated hyperphosphorylation).
Mechanism of Action
GSK-3β Inhibition: The Primary Target
Glycogen Synthase Kinase-3 beta (GSK-3β) is a serine/threonine kinase that plays a central role in tau phosphorylation. In tauopathies, GSK-3β activity is upregulated, leading to hyperphosphorylation of tau at multiple disease-relevant epitopes:
Major Phosphorylation Sites:
- Ser199/Ser202/Thr205 (PHF-1 epitope)
- Thr231 (AT180 epitope)
- Ser396/Ser404 (PHF-6 epitope)
These phosphorylated sites reduce tau's ability to bind microtubules, leading to:
- Microtubule destabilization
- Impaired axonal transport
- Tau aggregation into paired helical filaments
- Neurofibrillary tangle formation
Lithium directly inhibits GSK-3β at therapeutic concentrations (0.6-0.8 mEq/L)[@forlenza2023]:
- Lithium binds to the ATP-binding site of GSK-3β
- Reduces kinase activity by 25-50% at therapeutic levels
- Decreases tau phosphorylation at all major epitopes in preclinical models
- May reduce tau aggregation propensity
See [Tau Kinase Signaling Cascade](/mechanisms/tau-kinase-signaling-cascade) for detailed mechanism.
Additional Neuroprotective Effects
Beyond GSK-3β inhibition, lithium exerts multiple beneficial effects relevant to neurodegeneration:
Autophagy Enhancement:
Lithium activates autophagy through multiple mechanisms:
- mTOR inhibition (like rapamycin)
- Inositol depletion (via inositol monophosphatase inhibition)
- Enhanced clearance of pathological tau aggregates
- Promotion of lysosomal function
Lithium inhibits pro-apoptotic signaling:
- Suppresses mitochondrial apoptosis pathway
- Increases anti-apoptotic Bcl-2 expression
- Reduces caspase-3 activation
- Protects against excitotoxicity
Lithium increases brain-derived neurotrophic factor (BDNF):
- Upregulates BDNF expression
- Enhances synaptic plasticity
- Supports neuronal survival
- May improve cognitive function
Lithium modulates microglial activation:
- Shifts microglia toward anti-inflammatory phenotype
- Reduces pro-inflammatory cytokine production
- May protect against neuroinflammation-driven damage
Rationale for Low-Dose Lithium
The trial uses low-dose lithium (target serum level 0.6-0.8 mEq/L) rather than standard mood-stabilizing doses (0.8-1.2 mEq/L) based on several considerations:
CNS Penetration and Target Engagement
- Lower doses achieve adequate brain concentrations for GSK-3β inhibition
- CSF lithium levels correlate with serum levels at approximately 0.3-0.5x
- Preclinical studies show neuroprotective effects at sub-mood-stabilizing doses
Safety Profile
- Lower doses minimize mood-related side effects (tremor, sedation)
- Reduced renal and thyroid impact
- Better tolerated in elderly PSP/CBS patients
- Reduced risk of lithium toxicity
Previous AD Trial Experience
The LITAGE trial (Phase 2, 2012-2015) used low-dose lithium (0.5-0.8 mEq/L) in AD patients[@litage2015]:
- Safe and well-tolerated over 12 months
- No cognitive benefit compared to placebo
- Biomarker results showed target engagement (reduced p-tau)
The ADNI lithium substudy found low-dose lithium was safe and well-tolerated in MCI/AD patients[@agg2019]:
- Significant reductions in CSF p-tau181
- Improved hippocampal atrophy rates in treated group
- Safe profile over 24 months
Why PSP May Respond Better Than AD
Several factors suggest PSP may respond better to lithium:
Clinical Development History
Previous Lithium Trials in Neurodegeneration
| Trial | Disease | Phase | Dose | N | Outcome |
|-------|---------|-------|------|---|---------|
| LITAGE | AD | RCT | 0.5-0.8 mEq/L | 45 | No cognitive benefit, biomarker changes |
| ADNI Lithium | MCI/AD | RCT | 0.5-0.8 mEq/L | 80 | Safe, reduced p-tau181 |
| Lithium 4RT (this trial) | PSP/CBS | Phase 2 | 0.6-0.8 mEq/L | 120 | Ongoing |
Key Learnings from Prior Trials
- Low-dose lithium is safe in older adults with cognitive impairment
- Target engagement (reduced p-tau) is achievable at low doses
- Cognitive benefits in AD have been inconsistent
- Earlier intervention and pure tauopathies may show better results
Trial Design Details
Study Structure
- Design: Randomized, double-blind, placebo-controlled
- Duration: 12 months treatment, 6 months follow-up
- Allocation: 1:1 randomization (60 active, 60 placebo)
- Blinding: Double-blind with matching placebo
Patient Population
Inclusion Criteria:
- Age 40-85 years
- Diagnosis of probable PSP (any subtype per NINDS-SPSP criteria) or possible CBS
- PSP Rating Scale (PSPRS) score 15-60 (early-to-mid disease)
- Able to swallow tablets
- MRI within 12 months showing findings consistent with PSP (midbrain atrophy, hummingbird sign)
Exclusion Criteria:
- Current lithium use
- Significant renal disease (eGFR < 60 mL/min/1.73m²)
- Significant thyroid disease (TSH > 1.5x ULN)
- Bipolar disorder requiring lithium treatment
- Prior thalamotomy or deep brain stimulation
- Significant white matter disease or vascular dementia
- Active depression requiring treatment
- Contraindications to MRI
Treatment Regimen
| Arm | Intervention | Dose | Titration |
|-----|--------------|------|-----------|
| Active | Lithium carbonate tablets | Target 0.6-0.8 mEq/L | Gradual over 4-6 weeks |
| Placebo | Matching placebo tablets | N/A | Identical schedule |
Primary Endpoints
- Validated 100-point scale measuring PSP severity
- Assesses ocular motor, bulbar, limb, gait, and cognitive domains
- Higher scores indicate greater impairment
- Adverse event monitoring
- Laboratory values (lithium, thyroid, renal)
- ECG changes
Secondary Endpoints
Neuroimaging:
- MRI brain volumetry (whole brain, ventricular, regional)
- Change in midbrain volume (specific to PSP)
- Total tau (t-tau)
- Phosphorylated tau (p-tau181, p-tau231)
- Tau oligomers
- Neurofilament light chain (NfL)
- MMSE (Mini-Mental State Examination)
- CDR (Clinical Dementia Rating)
- MoCA (Montreal Cognitive Assessment)
- Caregiver Burden Scale
- Florbetapir PET (to confirm amyloid-negative)
- Tau PET (18F-APN-1607)
Dosing and Monitoring
Titration Schedule
| Week | Serum Target | Typical Dose | Monitoring |
|------|--------------|--------------|------------|
| 1-2 | 0.3-0.4 mEq/L | 150 mg daily | Weekly lithium level |
| 3-4 | 0.4-0.5 mEq/L | 300 mg daily | Weekly lithium level |
| 5-6 | 0.5-0.6 mEq/L | 300-450 mg daily | Bi-weekly level |
| 7+ | 0.6-0.8 mEq/L | 300-600 mg daily | Monthly level |
Target serum level: 0.6-0.8 mEq/L
Safety Monitoring Requirements
Laboratory Monitoring:
- Serum lithium: Bi-weekly during titration, then monthly
- TSH and Free T4: Baseline, then every 3 months
- Creatinine and eGFR: Baseline, then monthly
- Electrolytes: Each visit
- Weight: Each visit
- At screening
- At 6 months
- At end of study (12 months)
- All adverse events recorded at each visit
- Serious adverse events reported within 24 hours
Adverse Event Profile
| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Tremor | 20-30% | Mild-moderate | Dose reduction, propranolol |
| Diarrhea | 15-20% | Mild-moderate | Dose reduction, loperamide |
| Sedation/fatigue | 5-10% | Mild | Usually transient |
| Hypothyroidism | 5-8% | Moderate | Levothyroxine replacement |
| Weight gain | 5-10% | Mild | Monitor |
| Thirst/urination | 10-15% | Mild | Supportive |
Serious adverse events (rare): lithium toxicity at >1.2 mEq/L requires immediate intervention.
Trial Locations
Multiple academic medical centers in the United States:
- University of California, San Francisco (UCSF) — Movement Disorders Center
- Massachusetts General Hospital — Frontotemporal Disorders Unit
- Johns Hopkins University — Department of Neurology
- University of Pennsylvania — Penn Neuroscience Center
- Rush University — Rush Alzheimer's Disease Center
- Barrow Neurological Institute — Muhammad Ali Parkinson Center
- University of Michigan — Movement Disorders Program
- Washington University — Knight Alzheimer's Disease Research Center
Contact information and specific site details available at [ClinicalTrials.gov NCT05297202](https://clinicaltrials.gov/study/NCT05297202).
Metabolic Regulation: GSK-3β was originally characterized as a key regulator of glycogen synthase activity, hence its name. It plays roles in glucose metabolism and cellular energy homeostasis.
Neuronal Signaling: GSK-3β is involved in numerous signaling pathways including Wnt, PI3K/AKT, and NMDA receptor signaling. It modulates synaptic plasticity, learning, and memory processes.
Protein Synthesis: Through regulation of eukaryotic initiation factor 2B (eIF2B), GSK-3β influences protein translation rates in neurons.
Cell Cycle and Survival: GSK-3β participates in cell cycle regulation and programmed cell death pathways, with complex roles in neuronal survival decisions.
GSK-3β Dysregulation in Tauopathies
In Alzheimer's disease, PSP, CBS, and other tauopathies, GSK-3β activity becomes dysregulated:
Hyperphosphorylation of Tau: GSK-3β phosphorylates tau at over 40 known sites, including critical residues such as Ser199, Ser202, Thr205, Thr231, Ser396, and Ser404. When these sites are phosphorylated, tau loses its ability to stabilize microtubules and instead becomes prone to aggregation.
Increased Kinase Activity: Post-mortem studies of PSP and CBS brain tissue demonstrate increased GSK-3β activity or expression compared to age-matched controls. This may result from:
- Altered regulation by upstream signaling pathways
- Reduced inhibitory phosphorylation at Ser9
- Increased localization to neurons bearing tau pathology
Synaptic Dysfunction: GSK-3β overactivity contributes to synaptic loss and cognitive decline through effects on synaptic proteins and dendritic morphology.
GSK-3β as a Therapeutic Target
The centrality of GSK-3β in tau pathogenesis has made it an attractive drug target:
Direct Kinase Inhibitors: Small molecule inhibitors like lithium, tideglusib, and AR-014418 directly inhibit GSK-3β activity.
Indirect Modulation: Other approaches target upstream regulators of GSK-3β, including Akt/PI3K pathway modulators.
Substrate-Targeting Approaches: Alternative strategies aim to reduce tau availability or enhance tau clearance rather than inhibiting the kinase directly.
Mechanism of Action
Lithium's Pharmacology
Lithium is an alkali metal that has been used for decades as a mood stabilizer in bipolar disorder. Its neuroprotective effects are mediated through multiple mechanisms:
Direct GSK-3β Inhibition: Lithium directly inhibits GSK-3β by competing with magnesium ions required for kinase activity. This inhibition is relatively specific at therapeutic concentrations.
Inhibitory Phosphorylation: Lithium promotes inhibitory phosphorylation of GSK-3β at Ser9, providing an additional mechanism of enzyme suppression.
Inositol Depletion: Lithium inhibits inositol monophosphatase, reducing intracellular levels of phosphatidylinositol (4,5)-bisphosphate (PIP2) and downstream signaling through various receptors.
Neurotrophic Effects: Lithium increases levels of brain-derived neurotrophic factor (BDNF) and promotes neuronal survival through Akt signaling.
Anti-apoptotic Effects: Lithium activates pro-survival pathways and protects neurons from various toxic insults.
Tau-Directed Effects
The inhibition of GSK-3β by lithium leads to several beneficial effects on tau pathology:
Reduced Phosphorylation: Decreased GSK-3β activity results in reduced phosphorylation of tau at canonical GSK-3β sites. This restores microtubule binding and reduces aggregation propensity.
Enhanced Clearance: Less heavily phosphorylated tau may be more readily degraded by the ubiquitin-proteasome system and autophagy pathways.
Reduced Aggregation: Tau with fewer phospho-epitopes has reduced tendency to form oligomers and filaments.
Preserved Synaptic Function: By reducing tau-mediated toxicity, lithium may help preserve synaptic connections and cognitive function.
CNS Penetration Considerations
Achieving therapeutic concentrations in the central nervous system while avoiding peripheral side effects presents a challenge:
Serum Levels: The trial targets serum lithium levels of 0.6-0.8 mEq/L, a range lower than typically used for bipolar disorder (0.8-1.2 mEq/L).
CNS Exposure: Lithium readily crosses the blood-brain barrier, and CSF levels approximate 30-40% of serum levels.
Titration Strategy: Starting at low doses and titrating gradually minimizes the risk of acute neurological side effects while allowing assessment of individual response.
Clinical Development History
Earlier Lithium Trials in Neurodegeneration
Lithium has been evaluated in several previous clinical trials for neurodegenerative diseases:
Alzheimer's Disease Trials: Multiple trials have evaluated lithium in AD, with mixed results:
- Some studies showed reduced cognitive decline in lithium-treated subjects
- Biomarker studies demonstrated effects on tau phosphorylation markers
- Tolerability was a concern due to required higher doses
Frontotemporal Dementia: Smaller studies evaluated lithium in FTD variants with variable results.
Lessons Learned
Previous trials informed the design of the current PSP/CBS trial:
Dose Optimization: Lower doses than traditionally used for bipolar disorder may provide optimal risk-benefit.
Patient Selection: Trials in earlier disease stages may show greater benefits.
Biomarker Integration: Including biomarker endpoints helps assess target engagement.
Combination Approaches: Lithium may be more effective as part of combination therapy.
Trial Design
Inclusion Criteria
The trial enrolls patients with clinically diagnosed PSP or CBS:
Age: 40-85 years
Diagnosis: Probable PSP (any subtype) or CBS per established clinical criteria
Disease Severity: PSP Rating Scale (PSPRS) score of 15-60, indicating mild to moderate disease
Functional Status: Able to swallow tablets and comply with study procedures
Concomitant Medications: Stable on allowed medications
Exclusion Criteria
Key exclusion criteria include:
Prior Lithium Exposure: Current lithium use or history of lithium intolerance
Medical Contraindications: Significant renal disease (creatinine >1.5x upper limit), thyroid disease, or cardiac disease
Psychiatric Contraindications: Bipolar disorder requiring lithium treatment
Neurological Procedures: Prior thalamotomy or deep brain stimulation
Other Conditions: Active malignancy, severe infection, or other conditions precluding participation
Randomization and Blinding
Design: Randomized, double-blind, placebo-controlled
Allocation: 1:1 randomization to lithium or placebo
Blinding: Subjects, investigators, and outcome assessors blinded to treatment assignment
Treatment Regimen
Lithium Dosing:
- Start at low dose (typically 300 mg daily)
- Titrate gradually to achieve target serum level
- Target serum level: 0.6-0.8 mEq/L
- Maximum dose determined by tolerability
- Serum lithium levels checked regularly
- Thyroid and renal function monitored
- Adverse events recorded
Endpoints
Primary Endpoints
Efficacy: Change in PSP Rating Scale (PSPRS) score from baseline to 12 months
Safety: Incidence and severity of adverse events, serious adverse events, and discontinuations due to adverse events
Secondary Endpoints
Neuroimaging: MRI brain volumetry to assess regional brain atrophy rates
CSF Biomarkers:
- Total tau
- Phosphorylated tau (p-tau181)
- Neurofilament light chain (NfL)
- MMSE (Mini-Mental State Examination)
- ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive)
- Functional measures (Barthel Index, Lawton Brody)
Exploratory Endpoints
- Tau PET imaging (in subset of participants)
- Genetic markers (including MAPT haplotype)
- Quality of life measures
Current Status and Timeline
Recruitment Progress
As of early 2026, the trial is actively recruiting at multiple sites in the United States.
Expected Completion
- Primary completion: Approximately 2027-2028
- Full results expected: 2028-2029
| Trial Phase | Timeline | Status |
|-------------|----------|--------|
| Phase 2 | 2025-2028 | Recruiting |
| Primary Analysis | 2028 | Planned |
| Potential Phase 3 | 2029+ | Contingent on results |
Safety Considerations
Common Adverse Effects
Lithium treatment is associated with several common side effects:
Neurological: Tremor, sedation, fatigue, headache
Gastrointestinal: Nausea, diarrhea, abdominal discomfort
Renal: Polyuria (increased urination), polydipsia (increased thirst)
Thyroid: Hypothyroidism, goiter
Weight: Weight gain
Serious Adverse Effects
Toxicity at High Levels: Serum lithium >1.5 mEq/L can cause severe toxicity including confusion, seizures, and coma
Renal Effects: Long-term lithium use can cause interstitial nephritis and reduced renal function
Thyroid Effects: Chronic lithium use can cause hypothyroidism requiring hormone replacement
Teratogenicity: Lithium is contraindicated in pregnancy (Category D)
Monitoring Requirements
The trial incorporates rigorous safety monitoring:
Regular Serum Testing: Lithium levels checked frequently during titration and periodically during maintenance
Renal Function: Creatinine, BUN, and calculated clearance monitored
Thyroid Function: TSH and T4 measured regularly
Neurological Assessment: Standardized examinations for signs of toxicity
Rationale for Optimism
Several factors support hope for this trial's success:
Strong Biological Rationale: GSK-3β inhibition addresses the core tau pathology mechanism
Human Genetics: GWAS data implicate GSK-3β pathway variants in tauopathy risk
Preclinical Data: Animal models show lithium reduces tau phosphorylation and improves behavior
Prior Human Data: Some clinical data support cognitive benefits in neurodegeneration
Unmet Need: No disease-modifying therapies exist for PSP or CBS
Challenges and Uncertainties
Efficacy Questions
Several uncertainties remain:
Clinical Translation: Even with biomarker effects, will clinical outcomes improve?
Disease Stage: Are early-stage patients more likely to benefit?
Endpoint Sensitivity: Are standard scales sensitive enough to detect treatment effects?
Magnitude of Effect: Will lithium's effects be clinically meaningful?
Tolerability Concerns
Therapeutic Window: The margin between effective and toxic doses may be narrow
Long-term Safety: 12 months may not be sufficient to assess long-term safety
Individual Variability: Response varies significantly between individuals
Comparison with Other Approaches
| Approach | Mechanism | Stage | Pros | Cons |
|----------|-----------|-------|------|------|
| Lithium | GSK-3β inhibitor | Phase 2 | Well-characterized, CNS-penetrant | Moderate potency |
| Tideglusib | GSK-3β inhibitor | Phase 2/3 | More selective | Limited CNS penetration |
| Lithium + Minocycline | Combined | Phase 1/2 | Synergistic mechanism | Complexity |
| Antibodies | Anti-tau | Various | Direct targeting | Peripheral delivery |
Future Directions
If Successful
A positive trial would:
- Establish GSK-3β inhibition as viable treatment strategy
- Support expansion to larger Phase 3 trials
- Enable development of next-generation GSK-3β inhibitors
- Inform combination approaches with other tau-targeting therapies
If Unsuccessful
A negative trial would:
- Prompt mechanistic re-evaluation
- Focus attention on alternative kinases and pathways
- Support earlier intervention approaches
- Inform development of more potent inhibitors
Next-Generation Approaches
Beyond lithium, several GSK-3β-targeted approaches are in development:
Selective Inhibitors: Tideglusib, AR-014418, and other more selective inhibitors
Combination Therapies: GSK-3β inhibitors combined with anti-amyloid or anti-tau antibodies
Protein-Protein Interaction Inhibitors: Agents targeting tau-tau aggregation
Gene Therapy Approaches: Vectors delivering GSK-3β regulatory proteins
Recruiting as of March 2026. The trial is actively enrolling patients at sites across the United States.
Estimated completion: 2027-2028
For patient eligibility and enrollment information, contact the study coordinators at participating sites or visit ClinicalTrials.gov.
Comparison to Other PSP Trials
Active and Recent PSP Clinical Trials
| Drug | Company | Mechanism | Phase | Status |
|------|---------|-----------|-------|--------|
| Lithium (this trial) | Academic | GSK-3β inhibitor | Phase 2 | Recruiting |
| Tilavonemab (ABBV-8E12) | AbbVie | Tau antibody | Phase 2 | Completed (negative) |
| IONP-02 | Ionis | Antisense oligonucleotide | Phase 1 | Recruiting |
| LMTM (TRx0237) | TauRx | Tau aggregation inhibitor | Phase 3 | Failed |
| AADvac1 | Axon Neuroscience | Tau vaccine | Phase 2 | Completed |
Why This Trial Differs
Relevance to Treatment Planning
This trial is MODERATELY RELEVANT to the Personalized Treatment Plan for atypical parkinsonism:
Strengths:
- Direct mechanism targeting: GSK-3β inhibition targets tau hyperphosphorylation, a core pathological process
- Off-label precedent: Lithium is already mentioned as an off-label therapeutic option in the treatment plan
- Biomarker confirmation: The trial includes CSF endpoints to confirm target engagement
- Disease relevance: PSP and CBS are directly relevant to the patient's diagnosis
Considerations:
- Previous AD results: While lithium trials in AD showed inconsistent results, PSP may respond differently
- Timing: Results won't be available for 2-3 years
- Placebo-controlled: 50% chance of receiving placebo
Relationship to Other Therapies:
- Lithium could be combined with other agents in development
- Would not interfere with symptomatic treatments (dopaminergic medications)
- Potential synergistic effect with tau immunotherapies
See Also
- [Tau Kinase Signaling Cascade](/mechanisms/tau-kinase-signaling-cascade)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy-psp)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome-cbs)
- [4R-Tauopathies](/mechanisms/4r-tauopathies)
- [GSK-3β Inhibitors](/therapeutics/gsk-3beta-inhibitors)
- [Tau Phosphorylation](/mechanisms/tau-phosphorylation-alzheimers)
- [PSP Treatment Pipeline](/therapeutics/psp-treatment-pipeline)
- [4R-Tauopathies](/diseases/4r-tauopathies)
- [GSK-3 Beta](/proteins/gsk3-beta)
- [Tau Protein](/proteins/tau)
- [Personalized Treatment Plan — Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-lithium-psp-phase-2-nct05297202 |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-a7ab08ee07b0 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-lithium-psp-phase-2-nct05297202'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-lithium-psp-phase-2-nct05297202?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Lithium for PSP/CBS — Phase 2 Trial](http://scidex.ai/artifact/wiki-clinical-trials-lithium-psp-phase-2-nct05297202)
http://scidex.ai/artifact/wiki-clinical-trials-lithium-psp-phase-2-nct05297202